Receiving a benralizumab injection during an acute asthma or COPD exacerbation with a blood eosinophil count of at least 300 cells/µL led to fewertreatment failures, according to results ...

Benralizumab, a monoclonal antibody, is already used for the long-term management of eosinophilic asthma, with studies still evaluating the effect of long-term management in eosinophilic COPD.

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial ...

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): A double-blind, double-dummy, active placebo-controlled randomised trial.

Benralizumab Beneficial for Eosinophilic Exacerbations of Asthma, COPD December 10, 2024 Treatment failures occurred in 74% and 45% of patients in the PRED and pooled BENRA groups, respectively ...

Bafadhel's team randomly assigned more than 150 asthma and COPD patients being treated in emergency departments of English hospitals into three groups: one received benralizumab and dummy tablets ...

A new way of treating serious asthma and chronic obstructive pulmonary disease (COPD) attacks could be a “game-changer” and is the first leap in treatment for 50 years, researchers say.

For the clinical trial, researchers divided asthma or COPD patients into one of three groups – one receiving benralizumab during a flare-up, another taking prednisolone tablets, and a third ...

After 28 days, respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better with benralizumab. After ninety days, there were four times fewer people in the benralizumab ...

Benralizumab, a monoclonal antibody, is already used for the long-term management of eosinophilic asthma, with studies still evaluating the effect of long-term management in eosinophilic COPD.